Tag: BTK

Paramagnetic rim lesions predict effectiveness of tolebrutinib

Presented By
Dr Jiwon Oh, University of Toronto, Canada
Trial
HERCULES, GEMINI
Conference
ACTRIMS 2025
Type
News article

28 March 2025 11:34

MS activity remains low on long-term fenebrutinib

Presented By
Prof. Amit Bar-Or, University of Pennsylvania, PA, USA
Trial
Phase 2, FENopta
Conference
ACTRIMS 2025
Type
News article

28 March 2025 11:22

Orelabrutinib highly effective in relapsing-remitting MS, based on MRI results

Presented By
Prof. Yan Xu, Peking Union Medical College Hospital, China
Trial
Phase 2
Conference
ACTRIMS 2025
Type
News article

28 March 2025 11:08

Tolebrutinib slows disability worsening in relapsing MS

Presented By
Dr Jiwon Oh, St. Michael's Hospital, Canada
Trial
Phase 3, GEMINI 1, GEMINI 2
Conference
ECTRIMS 2024
Type
Peer-reviewed article

18 November 2024 12:21

Tolebrutinib slows disability in non-relapsing SPMS

Presented By
Prof. Robert Fox, Cleveland Clinic, OH, USA
Trial
Phase 3, HERCULES
Conference
ECTRIMS 2024
Type
Peer-reviewed article

18 November 2024 12:13

First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL

Presented By
Prof. Paolo Ghia, University Vita-Salute San Raffaele, Italy
Trial
Phase 3, SEQUOIA
Conference
EHA 2024
Type
Peer-reviewed article

12 August 2024 14:27

ECHO: Can we expect a novel standard of care in newly diagnosed MCL?

Presented By
Prof. Michael Wang, University of Texas, TX, USA
Trial
Phase 3, ECHO
Conference
EHA 2024
Type
Peer-reviewed article

12 August 2024 14:26

BTK signalling as a novel target in hidradenitis suppurativa treatment

Presented By
Prof. Alexandra Kimball, Harvard Medical School, USA
Conference
AAD 2024
Type
Peer-reviewed article

22 April 2024 16:20

Promising results for olverembatinib in combination with venetoclax for Ph+ ALL

Presented By
Dr Xiaoyuan Gong, Chinese Academy of Medical Sciences, China
Trial
Phase 2
Conference
ASH 2023
Type
Peer-reviewed article

7 February 2024 15:02

Undetectable MRD on maintenance venetoclax, acalabrutinib, and obinutuzumab in the majority of R/R CLL participants

Presented By
Dr Moritz Fürstenau, University of Cologne, Germany
Trial
Phase 2, CLL2-BAAG
Conference
ASH 2023
Type
Peer-reviewed article

7 February 2024 15:01

Encouraging results for the addition of acalabrutinib to lenalidomide and rituximab in follicular lymphoma

Presented By
Dr Paolo Strati, MD Anderson Cancer Center, TX, USA
Trial
Phase 2
Conference
ASH 2023
Type
Peer-reviewed article

7 February 2024 15:00

SYMPATICO: Ibrutinib plus venetoclax boosts PFS in R/R mantle cell lymphoma

Presented By
Prof. Michael Wang, University of Texas, TX, USA
Trial
Phase 3, SYMPATICO
Conference
ASH 2023
Type
Peer-reviewed article

7 February 2024 14:59

Favourable QoL and bleeding outcomes for rilzabrutinib in ITP

Presented By
Prof. Michael Tarantino, University of Illinois, IL, USA
Trial
Phase 1/2, LUNA 2
Conference
ASH 2023
Type
Peer-reviewed article

7 February 2024 14:55

Fenebrutinib shows rapid reduction of new Gd+ T1 lesions

Presented By
Prof. Amit Bar-Or, University of Pennsylvania, PA, USA
Trial
Phase 2, FENopta
Conference
MSMilan 2023
Type
Peer-reviewed article

4 December 2023 11:09

Remibrutinib reduces itch, sleep problems, and activity impairment in patients with CSU

Presented By
Dr Ana Giménez-Arnau, Autonomous University and Pompeu Fabra University, Spain
Trial
Phase 2
Conference
EADV 2023
Type
Peer-reviewed article

28 November 2023 10:13

What every doctor should know about CLL in today’s treatment landscape

Expert
Dr Jennifer Brown, Dana-Farber Cancer Institute & Harvard University, MA, USA

21 August 2023 14:58

Zanubrutinib wins battle of BTK inhibitors in relapsed or refractory CLL/SLL

Presented By
Prof. Jennifer Brown, Dana Farber Cancer Institute, MA, USA
Trial
Phase 3, ALPINE
Conference
ASH 2022
Type
Peer-reviewed article

20 February 2023 11:40

Bruton’s tyrosine kinase inhibition: a novel treatment option for Sjögren’s syndrome?

Presented By
Prof. Thomas Dörner, Charité University Hospital, Germany
Trial
Phase 2, LOUiSSE
Conference
ACR 2022
Type
News article

1 December 2022 13:19

Novel first-line treatment option for mantle cell lymphoma 

Presented By
Prof. Michael Wang, Anderson Cancer Center, TX, USA
Trial
Phase 3, SHINE
Conference
ASCO 2022
Type
Peer-reviewed article

5 August 2022 14:30

Inhibition of Bruton’s tyrosine kinase: a new way of approaching SLE?

Presented By
Prof. Zangou Li , Peking University People’s Hospital, China
Conference
EULAR 2022
Type
Peer-reviewed article

21 July 2022 19:21

Triple-therapy improves PFS in fit, previously untreated CLL

Presented By
Prof. Barbara Eichhorst, University Hospital Cologne, Germany
Trial
Phase 3, GAIA/CLL13
Conference
EHA 2022
Type
News article

1 July 2022 11:43

Evobrutinib reduces volume of slowly expanding lesions

Presented By
Prof. Douglas Arnold, McGill University, Canada
Conference
AAN 2022
Type
Peer-reviewed article

2 June 2022 15:34

SEQUOIA: Zanubrutinib meets primary endpoint for treatment-naïve CLL/SLL

Presented By
Prof. Constantine Tam, Peter MacCallum Cancer Centre, Australia
Trial
Phase 3, SEQUOIA
Conference
ASH 2021
Type
Peer-reviewed article

4 February 2022 11:39

Investigational therapies superior to standard-of-care in double-exposed CLL

Presented By
Dr Meghan Thompson, Memorial Sloan Cancer Center, NY, USA
Conference
ASH 2021
Type
Peer-reviewed article

4 February 2022 11:36

Evobrutinib reduces relapses and MRI lesion activity

Presented By
Prof. Jens Kuhle (University Hospital Basel, Switzerland); Prof. Douglas Arnold (McGill University, Canada)
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 14:15

CSU: Novel agent targeting Bruton’s tyrosine kinase leads to disease control

Presented By
Prof. Marcus Maurer, Charité University Hospital, Germany
Trial
Phase 2
Conference
EADV 2021
Type
Peer-reviewed article

18 November 2021 13:33

Acalabrutinib as effective but better tolerated than ibrutinib in CLL

Presented By
Prof. John Byrd, Ohio State University Comprehensive Cancer Center, OH, USA
Trial
Phase 3, ELEVATE-RR
Conference
ASCO 2021
Type
Peer-reviewed article

12 August 2021 13:22

Escalating the ESCALADE trial: untreated diffuse large B-cell lymphoma

Presented By
Dr Laurie Sehn, University of British Columbia, Vancouver, Canada
Trial
Phase 3, ESCALADE
Journal
Physician's Weekly
Conference
ASCO 2021

6 August 2021 12:36

ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety compared with ibrutinib

Presented By
Dr. John Byrd , Ohio State University College of Medicine, USA
Trial
Phase 3, ELEVATE-RR
Journal
Physician's Weekly
Conference
ASCO 2021

6 August 2021 11:55

ELEVATE-TN: Long-term efficacy in chronic lymphocytic leukemia

Presented By
Dr. John Byrd, Ohio State University College of Medicine, USA
Trial
Phase 3, ELEVATE-TN
Journal
Physician's Weekly
Conference
ASCO 2021

6 August 2021 11:20

Favourable outcomes with zanubrutinib versus ibrutinib in patients with r/r CLL

Presented By
Prof. Peter Hillmen, University of Leeds, UK
Trial
Phase 3, ALPINE
Conference
EHA 2021
Type
Peer-reviewed article

5 August 2021 14:08

ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety versus ibrutinib

Presented By
Prof. Peter Hillmen, St James’s University Hospital, UK
Trial
Phase 3, ELEVATE-RR
Conference
EHA 2021
Type
Peer-reviewed article

5 August 2021 13:43

Promising chemo-free treatment options in r/r DLBCL

Presented By
Prof. Marco Ladetto, University del Piemonte Orientale, Italy
Trial
LOTIS-2
Conference
EHA 2021
Type
Peer-reviewed article

5 August 2021 11:17

Fenebrutinib at highest dose generally well tolerated

Conference
AAN 2021
Type
Peer-reviewed article

16 June 2021 11:49

Bruton’s tyrosine kinase inhibition promising for pemphigus vulgaris

Presented By
Prof. Dedee F. Murrell, St George Hospital, University of New South Wales, Australia
Trial
Phase 2, BELIEVE
Conference
AAD VMX 2021
Type
Peer-reviewed article

7 June 2021 10:48

Targeting cells in the CNS key to abrogate multiple sclerosis progression

Presented By
Prof. Tony Traboulsee , University of British Columbia, Vancouver, Canada
Conference
AAN 2021

29 April 2021 13:22

BTK inhibition provides clinically active and durable platelet response

Presented By
Dr David J. Kuter, Massachusetts General Hospital & Harvard Medical School, USA
Conference
ASH 2020
Type
Peer-reviewed article

18 February 2021 09:42

First long-term efficacy data of a BTK inhibitor

Presented By
Prof. Xavier Montalban , Hospital University Vall d’Hebron, Spain
Conference
ECF 2020
Type
News article

16 December 2020 16:10

Modulating BTK-dependent inflammatory signalling in microglia

Conference
MS Virtual 2020
Type
Peer-reviewed article

25 November 2020 16:49

Zanubrutinib versus ibrutinib in Waldenström macroglobulinaemia

Presented By
Prof. Meletios Dimopoulos, University of Athens, Greece
Trial
Phase 3, ASPEN
Conference
EHA 2020
Type
Peer-reviewed article

9 September 2020 12:10

Experimental MS treatments

Trial
MS-SPI; TG1101-RMS201
Conference
EAN 2019
Type
Peer-reviewed article

27 August 2019 19:36

Exciting survival data for ibrutinib vs placebo in treatment-naïve, early-stage CLL

Presented By
Dr Petra Langerbeins, University of Cologne, Germany
Trial
Phase 3, CLL12
Conference
EHA 2019
Type
Peer-reviewed article

9 August 2019 16:26

ASCEND study: Acalabrutinib improves progression-free survival in relapsed/refractory CLL

Presented By
Dr Paolo Ghia, Vita-Salute San Raffaele University, Italy
Trial
Phase 3, ASCEND
Conference
EHA 2019
Type
Peer-reviewed article

9 August 2019 15:28

Bruton’s tyrosine kinase inhibitor highly effective in pemphigus vulgaris

Presented By
Prof. Dedee Murrell, University of New South Wales, Australia
Conference
AAD 2019
Type
Peer-reviewed article

19 April 2019 15:36
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com